The Medicines Company To Review ORBACTIV™ (Oritavancin) Launch Readiness On Tuesday, September 16, 2014

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) has scheduled a conference call for Tuesday, September 16 at 7:30 a.m. Eastern Time to discuss plans for launching ORBACTIVTM (oritavancin) for injection, the first and only single-dose, FDA-approved antibiotic for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive pathogens.

The conference call will be available via phone and webcast. The dial-in information is listed below:

Help employers find you! Check out all the jobs and post your resume.